Inflammation and Comorbidity. Are There any Chances to Improve the Prognosis in Patients with Extremely High Cardiovascular Risk?
The review contains actual data on possible approaches aimed at improving the prognosis in a special category of patients with extremely high cardiovascular risk, as well as in patients with recent acute coronary syndrome combined with comorbidity, including multifocal atherosclerosis. Currently, th...
Main Authors: | M. V. Zykov, O. L. Barbarash |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2021-09-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2543 |
Similar Items
-
Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?
by: O. L. Barbarash, et al.
Published: (2020-09-01) -
Inflammation Beats Cholesterol: A Comment on the Unequivocal Driver of Cardiovascular Disease Risk
by: Mauro Vaccarezza, et al.
Published: (2023-03-01) -
Immunity: Psoriasis comorbid with atherosclerosis
by: Chunping Liu, et al.
Published: (2022-12-01) -
THE ROLE OF MULTIFOCAL ATHEROSCLEROSIS IN DEVELOPMENT OF UNFAVORABLE CARDIOVASCULAR OUTCOMES IN PATIENTS AFTER CORONARY BYPASS GRAFTING
by: L. S. Barbarash, et al.
Published: (2016-02-01) -
Psoriasis comorbid with atherosclerosis meets in lipid metabolism
by: Liuping Chen, et al.
Published: (2023-12-01)